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The combined pulmonary ﬁbrosis and emphysema (CPFE) was reported ﬁrst in 1990, but it has been comparatively
underestimateduntilrecently.Althoughthediagnosticﬁndingsofbothemphysematousandﬁbroticregionsaredetectablebyhigh-
resolution computed tomography (HRCT) of the chest, the degree of progressive ﬁbrosis, which increases with emphysematous
lesions, is diﬃcult to evaluate. In this study, we hypothesized that the biomarkers for pulmonary ﬁbrosis, surfactant protein D (SP-
D), and KL-6 would serve as good indicators of ﬁbrotic lesions in CPFE. We recruited 46 patients who had been diagnosed in our
hospital with both emphysema and ﬁbrosis by their CT scan image from April 2003 to March 2008. The correlation among their
pulmonary function tests, composite physiologic index (CPI), and the serum levels of SP-D and KL-6 was evaluated. We found a
correlation between KL-6 and %VC, %TLC, or CPI and between SP-D and %VC or CPI. Interestingly, the combined product of
KL-6 and SP-D (KL-6xSP-D) was found to highly correlate with %VC and %TLC or CPI. These results show that both KL-6 and
SP-D, and especially the product of SP-D and KL-6, are good indicators of the presence of ﬁbrotic lesions in the lungs of CPFE
patients.
1.Introduction
Since the combined pulmonary ﬁbrosis and emphysema was
ﬁrst reported as “combined cryptogenic ﬁbrosing alveolitis
and emphysema” by Wiggins et al. in 1990 [1], the disease
has come to be generally recognized worldwide and was
listed as “an atypical phenotype of idiopathic interstitial
pneumonia” in the 3rd version of the Clinical Guideline
for Idiopathic Interstitial Pneumonia, published in 1991 by
the Diﬀuse Pulmonary Disease Group of the Ministry of
Health, Labour and Welfare of the Japanese Government.
However, the disease was underidentiﬁed until 2005, when
Cottinetal.reportedaretrospectivestudyof61patientswith
both emphysema and pulmonary ﬁbrosis and described the
syndrome comprehensively [2]. The diagnosis is based on
high-resolutioncomputedtomography(HRCT)ofthechest,
with ﬁndings that indicate emphysema of the upper lobe and
pulmonary ﬁbrosis of the lower lobe. CPFE is characterized
by a relatively well-preserved lung volume, severely impaired
carbon monoxide transfer, signiﬁcant decrease in PaO2 on
exercise, and a high prevalence of pulmonary hypertension
leading to a poor prognosis [3, 4]. We expect that the extent
of pulmonary ﬁbrosis in CPFE patients might inﬂuence the
outcome,becausepatientswithCPFEhaveaworseprognosis
than patients with emphysema [5]. However, it is diﬃcult to
evaluate the extent of pulmonary ﬁbrosis in patients with
CPFE. Vital capacity and DLco are closely inﬂuenced by
emphysematous change. Wells et al. proposed the composite
physiologic index (CPI), calculated from the individual
predicted percentage values for VC, DLco, and FEV1.0 as
a new indicator of the extent of pulmonary ﬁbrosis, and
this index was shown to represent the extent of pulmonary
ﬁbrosis on HRCT, adjusting for emphysema [6].
KL-6/MUC-1 (KL-6) and surfactant protein D (SP-D)
are useful biomarkers in the diagnosis of various types of
interstitial lung disease (ILD), including IPF [7]. KL-6 is2 Pulmonary Medicine
a circulating high-molecular glycoprotein, classiﬁed as
humanMUC-1[8,9].KL-6isexpressedonthesurfacemem-
brane of alveolar epithelial cells and bronchiolar epithelial
cells. SP-D belongs to the subgroup of the C-type lectin
superfamily. It is secreted from Clara cells and alveolar
epithelial cells. These biomarkers are reportedly elevated in
IPF patients and related to the severity of pulmonary ﬁbrosis
[10]. In this context, we expected that KL-6 and SP-D would
prove to be useful biomarkers for the evaluation of the extent
of pulmonary ﬁbrosis in patients with CPFE.
2. Patientsand Methods
2.1. Patients Examined. We retrospectively analyzed 46
patients with CPFE who had been diagnosed as having both
emphysema and ﬁbrosis on their HRCT images in order to
evaluate the correlation between the serum biomarkers (KL-
6, SP-D) and pulmonary function indices, or CPI, which
represents pulmonary ﬁbrosis in patients with CPFE. The
patients examined were obtained from the clinical data
recorded at Tohoku University Hospital from April 2003 to
March2008.Exclusioncriteriaincludedthepresenceofother
interstitial lung disease, including drug-induced interstitial
lung disease, hypersensitivity pneumonitis, pneumoconio-
sis,sarcoidosis,pulmonaryhistiocytosis,lymphangioleiomy-
omatosis, and eosinophilic pneumonia, or other obvious
causes.
2.2. Radiological Assessment. High-resolution computed
tomography (HRCT) scans of the chest were reviewed inde-
pendentlybyﬁvepulmonologists(SC,HO,SH,SO,andME).
Cases were deemed acceptable for inclusion if the following
criteria were met: (1) presence of emphysema on CT scan
deﬁned as well-demarcated areas of decreased attenuation in
comparison with contiguous normal lung and characterized
by a very thin (1mm) or no margin, and/or multiple bullae
(1cm) with upper zone predominance; (2) presence of a
diﬀuse parenchymal lung disease with signiﬁcant pulmonary
ﬁbrosis on HRCT scan, deﬁned as reticular opacities with
peripheral and basal predominance, honeycombing, archi-
tectural distortion, and/or traction broncho-bronchiolo-
ectasis; focal ground-glass opacities and/or areas of alveolar
condensation may be present but should not be prominent.
No patient had atelectasis secondary to a central lung cancer
at the time of the initial diagnosis.
2.3. Clinical Assessment. Medical records were analyzed
r e t r o s p e c t i v e l y .T h ed a t aw h i c hw a se x t r a c t e di n c l u d e d
age, gender, smoking history, laboratory results, pulmonary
function tests, PaO2, and PaCO2 at rest. Access to patients’
medical records was approved by the Tohoku University
School of Medicine, and patient conﬁdentiality was carefully
maintained.
2.4. Measurements. The serum levels of KL-6 and SP-D
were determined with commercially available ELISA kits. We
deﬁnedahighKL-6valueasbeingover500U/mL,andahigh
Table 1: Clinical characteristics at diagnosis in CPFE patients.
Subjects, n 46
Gender, male/female 42/4
Age, years 67 ±8.7
Smoker (%) 100
Smoking status, current/former 20/26
Smoking history, pack years 58.8 ±33.9
PaO2 (Torr) 82.3 ±12.3
PaCO2 (Torr) 38.7 ±2.8
KL-6 (U/mL) 1160 ±1104
SP-D (ng/mL) 186 ±107
Lung cancer, n (%) 24 (52.2)
SP-D value as over 110ng/mL. The composite physiologic
index (CPI) was calculated as follows [6]:
CPI = 91.0 − 0.65 ×%DLco −0.53 ×%VC
+0 .34 ×%FEV1.0.
(1)
2.5. Statistical Analysis. Univariate correlations between
variables were compared using Spearman’s rank correlation
coeﬃcient. Comparisons between groups were performed
using Student’s unpaired t-test. All tests were two sided
and performed at the 0.05 signiﬁcance level. All data are
expressed as the means ± SD.
3. Results
3.1. Imaging Characteristics of the CPFE Patients. The diag-
nosis of CPFE was determined by HRCT scan which
indicated the chief distribution of emphysema in the upper
zones and pulmonary ﬁbrosis in the lower zones of lungs.
The prevalence of honeycombing, ground-glass opacities,
and reticular opacities was particularly high. Typical HRCT
scan images of these CPFE patients are shown in Figure 1.
3.2. Clinical Presentation and Pulmonary Function Test in
CPFE. The clinical status and laboratory ﬁndings of the
patients at the time of the initial diagnosis are presented in
Table 1. Five patients had histologically diagnosed IPF/UIP.
All patients had a history of smoking, and the current and
former smokers made up 20 (43.5%) and 26 (56.5%) of
the total, respectively. The partial pressure of oxygen in the
arterial blood at rest and the partial pressure of carbon
dioxide in the arterial blood at rest were within the normal
range. The level of KL-6 was 1160 ± 1104U/mL, while the
SP-D level was 186 ± 107ng/mL. Eight patients (17.4%)
developed lung cancer after the original diagnosis, and 16
patients already had lung cancer at the time of diagnosis.
Squamouscellcarcinomawasthemostcommontype(42%),
and adenocarcinoma was the second (33%).
The pulmonary function tests (PFTs) are described in
Table 2. In spite of the fact that all patients had emphysema
and ﬁbrosis on the HRCT, the result showed that only thePulmonary Medicine 3
(a) (b)
Figure 1: Imaging from a 64-year-old man with CPFE. (a) HRCT of bilateral upper lung ﬁelds shows emphysema. (b) HRCT of bilateral
lower lung ﬁelds shows traction bronchiectasis and honeycomb and reticular opacities.
Table 2: Pulmonary function tests in CPFE patients.
%VC 94.7 ±16.6
%FVC 94.2 ±16.7
%FEV1.0 96.4 ±18.4
FEV1.0/FVC (%) 78.2 ±10.5
%RV 95.5 ±33.2
%TLC 90.7 ±16.1
%RV/TLC 92.5 ±24.7
%DLco 67.0 ±17.0
%DLco/VA 66.7 ±14.8
VC: vital capacity; FVC: forced vital capacity.
FEV1.0: forced expiratory volume in one second.
RV: residual volume; TLC: total lung capacity.
DLco: diﬀusing capacity for carbon monoxide.
VA: alveolar volume.
%DLco decreased signiﬁcantly among the PFT parameters, a
ﬁnding which is in agreement with several other studies.
3.3. Comparison between CPFE Patients without Lung Cancer
and with Lung Cancer at Diagnosis. To analyze the inﬂuences
of lung cancer on clinical presentation and pulmonary
function test, we classiﬁed these 46 patients into two groups,
agroupofCPFEpatientswithoutlungcancer(CPFEwithout
CA) and that of CPFE patients with lung cancer (CPFE
with CA) at diagnosis. The clinical status and laboratory
ﬁndings, PFT, and CPI of these patients are summarized in
Table 3. There was no signiﬁcant diﬀerence in age and the
level of serum SP-D, %VC, %FVC, %FEV1.0,F E V 1.0/FVC
(%), %DLco, and CPI between the CPFE without CA and
CPFE with CA groups; however, %FRC and %RV/TLC were
signiﬁcantly lower in the CPFE without CA group. On the
other hand, the level of serum KL-6 was signiﬁcantly higher
in the CPFE without CA group. Smoking history (pack
years) was higher in CPFE with CA group without statistic
diﬀerence.
3.4. Correlation of the Pulmonary Function Tests with KL-
6 and SP-D. Among these patients, 20% had a high KL-6
value,20%hadahighSP-Dvalue,and51%hadboth.91%of
Table 3:Ageandsmokinghistory,KL-6,SP-D,pulmonaryfunction
tests, CPI in CPFE without lung cancer (CPFE without CA), and
CPFE with lung cancer (CPFE with CA) at diagnosis.
CPFE without CA CPFE with CA P value
Age, years 66.6 ±8.46 7 .3 ±9.30 . 8 2
Smoking history,
pack years 50.9 ±21.47 3 .6 ±46.70 . 0 8
KL-6 (U/mL) 1443 ±1234 629 ±384 0.002
SP-D (ng/mL) 199.9 ±108.7 160.1 ±98.10 . 2 3
%VC 94.5 ±14.79 5 .3 ±19.40 . 8 7
%FVC 93.9 ±15.19 4 .8 ±19.90 . 8 8
%FEV1.0 97.0 ±13.89 5 .1 ±25.10 . 8 1
FEV1.0/FVC (%) 79.6 ±9.27 5 .4 ±12.10 . 2 2
%FRC 77.8 ±20.1 100 ±32.10 . 0 2
%RV/TLC 83.8 ±18.9 108.5 ±25.3 0.003
%DLco 67.4 ±14.96 6 .4 ±20.10 . 8 6
CPI 30.2 ±12.53 0 .5 ±15.40 . 9 5
the patients had high biomarker values for pulmonary ﬁbro-
sis (Figure 2). There was a signiﬁcant negative correlation
b e t w e e nK L - 6a n d% V C( r =− 0.34, P = 0.028), %FRC
(r =− 0.40, P = 0.03), %RV (r =− 0.56, P = 0.001),
%TLC (r =− 0.53, P = 0.002), %RV/TLC (r =− 0.36,
P = 0.03), and %DLco (r =− 0.33, P = 0.036) (Table 4).
There was a signiﬁcantly negative correlation between
SP-D and %VC (r =− 0.33, P = 0.03) and a signiﬁ-
cant correlation between SP-D and FEV1.0/FVC (%) (r =
0.34, P = 0.03). In a similar manner, the combined
product of KL-6 and SP-D (KL-6xSP-D) was also examined.
There was a signiﬁcant correlation between KL-6xSP-D and
FEV1.0/FVC (%) (r = 0.4, P = 0.01) and a signiﬁcant
negative correlation between KL-6xSP-D and %VC (r =
−0.43, P = 0.005), %FRC (r =− 0.41, P = 0.01), %RV
(r =− 0.48, P = 0.004), %TLC (r =− 0.6, P<0.001), or
%DLco (r =− 0.32, P = 0.046). There was a trend toward
an inverse correlation between KL-6xSP-D and %RV/TLC
(r =− 0.32, P = 0.06)(Table 4).WeusedtheCPItoevaluate
the extent of the pulmonary ﬁbrosis in the patients with
CPFE. There were signiﬁcant correlations between CPI and4 Pulmonary Medicine
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Figure 2: Ratio of patients with high serum levels of KL-6 and SP-
D.
Table 4: Correlation of pulmonary function tests with KL-6 and
SP-D.
Spearman rank correlation coeﬃcient
KL-6 SP-D KL-6xSP-D
%VC
−0.34 −0.33 −0.43
P = 0.028 P = 0.03 P = 0.005
FEV1.0/FVC (%) 0.21 0.34 0.40
P = 0.17 P = 0.03 P = 0.01
%FRC
−0.40 −0.16 −0.41
P = 0.03 P = 0.36 P = 0.01
%RV
−0.56 −0.09 −0.48
P = 0.001 P = 0.58 P = 0.004
%TLC
−0.53 −0.29 −0.60
P = 0.002 P = 0.09 P = 0.0004
%RV/TLC
−0.36 −0.04 −0.32
P = 0.03 P = 0.83 P = 0.06
%DLco
−0.33 −0.09 −0.32
P = 0.036 P = 0.57 P = 0.046
KL-6xSP-D: the combined product of KL-6 and SP-D.
KL-6 (r = 0.461, P = 0.005), SP-D (r = 0.337, P = 0.04),
and KL-6xSP-D (r = 0.562, P<0.001) (Table 5).
4. Discussion
In this study, the importance of both of the biomarkers SP-D
and KL-6 is demonstrated, and the product of KL-6xSP-D is
shown to be a good indicator for an estimation of the degree
of ﬁbrosis in CPFE, a result which is in close correlation with
the CPI.
Table 5: Correlation of composite physiologic index with KL-6 and
SP-D.
Spearman rank correlation coeﬃcient
KL-6 SP-D KL-6xSP-D
CPI 0.461 0.337 0.562
P = 0.005 P = 0.04 P = 0.0006
CPI: composite physiologic index.
KL-6xSP-D: the combined product of KL-6 and SP-D.
We checked the clinical characteristics of the 46 patients
with CPFE who visited our hospital and analyzed them to
determine whether KL-6 and SP-D are useful biomarkers for
CPFE, as they are for IPF. The prevalence of lung cancer in
patients with CPFE was quite high (52.2%) in our study, and
squamous cell carcinoma was the most common histological
type. Kitaguchi et al. retrospectively reviewed the record of
47 patients with CPFE and found that 22 of those patients
(46.8%) had lung cancer. Squamous cell carcinoma was also
the most common histological type in their study [4]. The
prevalenceofCPFEinpatientswithlungcancerwasreported
by Usui et al., who found 101 CPFE cases (8.9%) out of 1143
lung cancer patients [11]. All of the patients with CPFE were
current or former smokers, and most of them were male.
Smoking accounted for the high prevalence of lung cancer in
these patients with CPFE, but some genetic susceptibility to
chronic smoking-induced inﬂammation might be involved
in the association of CPFE with lung cancer. To take one
example of such a factor, a genome-wide association study
identiﬁed an association between a common variant of the
telomerase-related TERT gene and susceptibility to IPF [12].
ShortenedtelomeresareariskfactorforIPFandareasso-
ciated with COPD and lung cancer [13–15]. Further studies
are required to elucidate whether CPFE is an independent
risk factor for lung cancer. Similarly to other studies, only
%DLcowassigniﬁcantlylowamongthepulmonaryfunction
parameters in our study. In spite of certain HRCT ﬁndings,
pulmonaryfunctionsinpatientswithCPFE,exceptforDLco,
were preserved [2, 4]. Pulmonary function tests were inﬂu-
enced both by ﬁbrotic lesions and emphysematous lesions.
It is likely that the hyperinﬂation and high compliance of
the emphysematous lesions in the CPFE lungs compensate
for the volume loss and low compliance of the ﬁbrotic
lesions.Incontrast,bothemphysematousandﬁbroticlesions
in the CPFE lungs attenuated the DLco progressively and
synergistically.
Other study has implied that KL-6 also rises as a tumor
marker for lung cancer [16]. The group of CPFE with CA
may have been higher-serum KL-6. However, contrary to
anticipation, serum KL-6 was signiﬁcantly lower in CPFE
with CA group. This result showed that the complication
of lung cancer had only limited inﬂuence on KL-6 value in
our study. Compared with pulmonary ﬁbrosis, lung cancer is
more frequently pointed out by chest X-rays in the medical
checkup. As a result, the patients of CPFE with CA might be
discovered at an early stage of pulmonary ﬁbrosis.
TheserumKL-6levelintheCPFEpatientswasnegatively
correlated with %VC, %FRC, %RV, %TLC, %RV/TLC, andPulmonary Medicine 5
%DLco although they were within the normal limit. KL-6 is
a high molecular weight, mucin-like glycoprotein expressed
by alveolar epithelial and bronchiolar epithelial cells. KL-6
is reported to be highly expressed by regenerative type II
pneumocytes in lung sections from patients with interstitial
lung disease [8]. Epithelial breakdown might result in a
leakage of KL-6 into the circulation, an eﬀect which can
be determined with a commercially available ELISA kit.
Serum KL-6 was found to be elevated in various interstitial
lung diseases including IPF, nonspeciﬁc interstitial pneumo-
nia (NSIP), collagen vascular disease-associated interstitial
pneumonia (CVD-IP), and drug-induced and radiation-
induced pneumonitis. In 21 patients with IPF and 12
patients with CVD-IP, serum KL-6 was signiﬁcantly elevated
compared to healthy controls and patients with bacterial
pneumonias [7]. Satoh et al. reported an increased mortality
in patients with IIPs, including patients with IPF, with KL-
6l e v e l s> 1000U/mL [17]. Elevations in KL-6 also were
associatedwithNSIP.InﬁbroticNSIP,KL-6waselevatedand
correlated with the extent of ﬁbrotic change on HRCT [18].
The serum SP-D of CPFE patients was negatively cor-
related with %VC. SP-D and surfactant protein A (SP-A)
are water-soluble members of the C-type lesion superfamily
and produced in the lung by alveolar epithelial type II cells.
They are thought to be important constituents of the innate
immunity of the lung [10]. The serum SP-D and SP-A levels
are increased in various interstitial lung diseases, probably
due to type II pneumocytic hyperplasia and a disturbed
epithelial barrier. SP-D and SP-A are useful biomarkers in
patients with interstitial lung diseases [19]. Takahashi et al.
showed that the SP-D concentration was related to both the
extent of parenchymal collapse and the rate of deterioration
p e ry e a ri np u l m o n a r yf u n c t i o n[ 20].
The composite physiologic index (CPI) correlates with
the extent of ﬁbrotic change on CT scan more closely and
is better linked to mortality than individual pulmonary
function indices [21]. Wells et al. constructed a CPI for the
morphologic severity of disease to quantitatively calibrate
pulmonary ﬁbrosis using pulmonary function tests [6].
The CPI was derived in 106 patients with a clinical and
CT diagnosis of IPF. The CPI accounts for coexisting
emphysema, which exerts a major confounding inﬂuence on
pulmonary function indices. The CPI was also used in the
analysisperformedintheIFIGENIAstudy[22].Thisanalysis
revealed that patients with a low CPI had a better prognosis.
The combined product of KL-6 and SP-D (KL-6xSP-D)
was more closely correlated with the CPI than KL-6 or SP-
D alone. KL-6 and SP-D are both biomarkers of pulmonary
ﬁbrosis, but a dissociation of these biomarkers is frequently
observed. We recently showed that KL-6 was signiﬁcantly
higherinsymptomaticthanasymptomaticIPFpatients,even
though the SP-D level was elevated in each group [23]. The
diﬀerence in the relative level and distribution pattern of KL-
6 and SP-D might explain this dissociation between them.
It is generally reported that SP-D is signiﬁcantly correlated
with alveolitis (a reversible change), and KL-6 is signiﬁcantly
correlated with chronic ﬁbrosis (an irreversible change) [20].
Therefore, KL-6xSP-D may more closely reﬂect the severity
of the disease and deterioration in pulmonary function.
In conclusion, it is shown that both KL-6 and SP-D are
useful biomarkers of the extent of pulmonary ﬁbrosis in
patients with CPFE. The resultsalso reveal that KL-6xSP-D is
highlycorrelatedwiththeCPI,whichreﬂectstheprogression
of pulmonary ﬁbrosis in CPFE patients more than either KL-
6 or SP-D by itself.
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